

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.
OMB 0651-0031

Approved for use through 07/31/2003. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	10/648,436
Sheet 1		of 2	Filing Date	8/21/2003	
			First Named Inventor	Gleave et al.	
			Art Unit	1645	
			Examiner Name		
			Attorney Docket Number	UBC.P-030	

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			

U.S. PATENT APPLICATION PUBLICATIONS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
		US-2002/0086356 A1	07/04/2002	Tuschi et al.	
		US-2003/0158130 A1	08/21/2003	Gleave et al.	
		US-			
		US-			
		US-			
		US-			
		US-			


FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Country Code ³	Number ⁴ - Kind Code ⁵ (if known)			
KC		WO	00/49937 A2	8/31/2000	The University of British Columbia	
KC		WO	01/05435 A2	1/25/2001	The University of British Columbia	
KC		WO	02/22642 A1	3/21/2002	The University of British Columbia	

Examiner Signature	<i>Liberty Chay</i>	Date Considered	7-12-05
--------------------	---------------------	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



PTO/SB/08B (06-03)

Approved for use through 06/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

2

of

2

Complete if Known

Application Number	10/646,436
Filing Date	8/21/2003
First Named Inventor	Gleave et al.
Art Unit	1645
Examiner Name	
Attorney Docket Number	UBC.P-030

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
KC		CARTHEW, Gene silencing by double-stranded RNA, Current Opinion in Cell Biology, 2001, Page(s) 244-248, Volume 13	
KC		DEMATOS ET AL., Clusterin promotes amyloid plaque formation and is critical for neuritic toxicity in a mouse model of Alzheimer's disease, PNAS, 2002, Page(s) 10843-10848, Volume 99, Number 16	
KC		ELBASHIR ET AL., Duplexes of 21 -nucleotide RNAs mediate RNA interference in cultured mammalian cells, Nature, 2001, Page(s) 494-498, Volume 411	
KC		FIRE ET AL., Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans, Nature, 1998, Page(s) 806-811, Volume 391	
KC		YANG ET AL., Nuclear clusterin/XIP8, an x-ray-induced Ku70-binding protein that signals cell death, PNAS, 2000, Page(s) 5907-5912, Volume 97, Number 11	

Examiner
Signature*Kiberl Chay*Date
Considered

7-12-05

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

(Use as many sheets as necessary)

Substitution for form 1449A/PTQ

Application Number	10/646,436
Filing Date	8/21/2003
First Named Inventor	Gleave et al.
Art Unit	1645
Examiner Name	
Attorney Docket Number	UBC.P-030

Sheet	1	of	2	Attorney Docket Number	UBC.P-030
-------	---	----	---	------------------------	-----------

[illegible][illegible]

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. * Applicant's unique citation designation number (optional). * See Kinds Codes of US PTO Patent Documents at www.uspto.gov or MPEP 901.04. * Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). * For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. * Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. * Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Application Number	10/648,438
		Filing Date	8/21/2003
		First Named Inventor	Gleave et al.
		Art Unit	1645
		Examiner Name	
Sheet 2 of 2	Attorney Docket Number	UBC.P-030	

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
KC		DAVIES ET AL., Mutations of the BRAF gene in human cancer, Nature, 2002, Page(s) 949-954, Volume 417	
KC		GEWIRTZ, A Critical Evaluation of the Mechanisms of Action Proposed for the Antitumor Effects of the Anthracycline Antibiotics Adriamycin and Daunorubicin, Biochemical Pharmacology, 1999, Page(s) 727-741, Volume 57	
KC		HARBORTH ET AL., Identification of essential genes in cultured mammalian cells using small interfering RNAs, Journal of Cell Science, 2001, Page(s) 4557-4565, Volume 114	
KC		LESKOV ET AL., Synthesis and Functional Analyses of Nuclear Clusterin, a Cell Death Protein, The Journal of Biological Chemistry, 2003, Page(s) 11590-11600, Volume 278, Number 13	
KC		MCGILL ET AL., Bcl2 Regulation by the Melanocyte Master Regulator Mitf Modulates Lineage Survival and Melanoma Cell Viability, Cell, 2002, Page(s) 707-718, Volume 109	
KC		MULLER ET AL., Cellular pharmacokinetics of doxorubicin in patients with chronic lymphocytic leukemia: comparison of bolus administration and continuous infusion, Cancer Chemother Pharmacol, 1993, Page(s) 379-384, Volume 32	
KC		ROHLFF ET AL., Prostate Cancer Cell Growth Inhibition by Tamoxifen Is Associated With Inhibition of Protein Kinase C and Induction of p21 ^{waf1/cip1} , The Prostate, 1998, Page(s) 51-59, Volume 37	

Examiner Signature	<i>Liberty Chang</i>	Date Considered	7-12-05
--------------------	----------------------	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete if Known

Application Number	10/646,436
Filing Date	8/21/2003
First Named Inventor	Gleave et al.
Art Unit	1645
Examiner Name	
Attorney Docket Number	UBC.P-030

Sheet

1

of

4

Attorney Docket Number

UBC.P-030

U.S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	1*
		Country Code* - Number* - Kind Code* (if known)				
KC		WO 01/75164 A2	10/11/2001	Whitehead Institute for Biomedical Research et al.		
KC		WO 02/22635 A1	3/21/2002	ISIS Pharmaceuticals, Inc.		
KC		WO 02/44321 A2	06/06/2002	Maxplanck-Gesellschaft Zur Forderung Der Wissenschaften E.V.		
KC		WO 03/062421 A1	7/31/2003	The University of British Columbia		

**Examiner
Signature**

Date
Considered

71205

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of US PTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449B/PTO		Complete If Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Application Number	10/646,436
		Filing Date	8/21/2003
		First Named Inventor	Gleave et al.
		Art Unit	1645
		Examiner Name	
Sheet 2 of 4	Attorney Docket Number	UBC-P-030	

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
KC		AGAMI, RNAi and related mechanisms and their potential use for therapy. Current Opinion in Chemical Biology, 2002, Page(s) 829-834, Volume 6, Publisher: Current Biology Ltd, London, GB XP00295888	
KC		BRUMMELKAMP ET AL., A system for stable expression of short interfering RNAs in mammalian cells, Science, 2002, Page(s) 550-553, Volume 296, Number 5567, Publisher: American Association for the Advancement of Science, US, XP002234902	
KC		CALERO ET AL., Apolipoprotein J (Clusterin) and Alzheimer's Disease, Microscopy Research and Technique, 2000, Page(s) 305-315, Volume 50, Number 4, XP009021345	
KC		CHOI-MIURA ET AL., Relationship Between Multifunctional Protein "Clusterin" and Alzheimer Disease, Neurobiology of Aging, 1996, Page(s) 717-722, Volume 17, Number 5, XP001146408	
KC		DEMIR ET AL., Use of RNA Interference (RNAi) to Disrupt C-Kit Gene Expression in Malignant Human Hematopoietic and Neuroepithelial Cells, Blood, 2000, Page(s) 378B, Volume 96, Number 11, Part 2, Publisher: W. B. Saunders Company, Orlando, FL, US, Abstract #5389, XP009004894	
KC		GLEAVE ET AL., Use of Antisense Oligonucleotides Targeting the Antiapoptotic Gene, Clusterin/Testosterone-Repressed Prostate Message 2, to Enhance Androgen Sensitivity and Chemosensitivity in Prostate Cancer, Urology, 2001, Page(s) 39-49, Volume 58, XP002262320	
KC		GLEAVE ET AL., Targeting anti-apoptotic genes upregulated by androgen withdrawal using antisense oligonucleotides to enhance androgen- and chemo-sensitivity in prostate cancer, Investigational New Drugs, 2002, Page(s) 145-158, Volume 20, Number 2, XP 009021411	
KC		HOJOH, RNA interference (RNAi) induction with various types of synthetic oligonucleotide duplexes in cultured human cells, FEBS Letters, 2002, Page(s) 195-199, Volume 521, Number 1-3, Publisher: Elsevier Science Publishers, Amsterdam, NL XP004362164	
KC		JONES ET AL., Molecules in focus: Clusterin, The International Journal of Biochemistry & Cell Biology, 2002, Page(s) 427-431, Volume 34, XP002262319	
KC		KOCH-BRANDT ET AL., Clusterin: A Role in Cell Survival in the Face of Apoptosis?, Process in Molecular and Subcellar Biology, 1996, Page(s) 130-149, Volume 16, XP009021385	
KC		MIYAKE ET AL., Antisense TRPM-2 Oligodeoxynucleotides Chemosensitize Human Androgen-independent PC-3 Prostate Cancer Cells Both in Vitro and in Vivo, Clinical Cancer Research, 2000, Page(s) 1655-1663, Volume 6, Number 5, Publisher: The American Association for Cancer Research, US, XP000960694	

Examiner Signature	<i>K. Berkeley Chong</i>	Date Considered	7-12-05
--------------------	--------------------------	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). * Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Approved for use through 06/30/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Application Number	10/646,436
		Filing Date	8/21/2003
		First Named Inventor	Gleave et al.
		Art Unit	1645
		Examiner Name	
Sheet 3 (Use as many sheets as necessary)	4	Attorney Docket Number	UBC.P-030

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
KC		MIYAKE ET AL., Novel therapeutic strategy for advanced prostate cancer using antisense oligodeoxynucleotides targeting antiapoptotic genes upregulated after androgen withdrawal to delay androgen-independent progression and enhance chemosensitivity., International Journal of Urology, 2001, Page(s) 337-349, Volume 8, Number 7, XP002262321	
KC		PADDISON ET AL., Stable suppression of gene expression by RNAi in mammalian cells, Proceedings of the National Academy of Sciences of USA, 2002, Page(s) 1443-1448, Volume 99, Number 3, Publisher: National Academy of Science, XP002958887	
KC		ROSENBERG ET AL., Clusterin: Physiologic and Pathophysiologic Considerations, Int. J. Biochem. Cell Biol., 1995, Page(s) 633-645, Volume 27, Number 7, XP001002844	
KC		SENSIBAR ET AL., Prevention of Cell Death Induced by Tumor Necrosis Factor α in LNCaP Cells by Overexpression of Sulfated Glycoprotein-2 (Clusterin), Cancer Research, 1995, Page(s) 2431-2437, Volume 55, Publisher: American Association for Cancer Research, Baltimore, MD, US, XP002930082	
KC		SHARP, RNAi and double-strand RNA, Genes and Development, 1999, Page(s) 139-141, Volume 13, Number 2, Publisher: Cold Spring Harbor Laboratory Press, New York, US, XP002171268	
KC		STROCCHI ET AL., Neuronal loss up-regulates clusterin mRNA in living neurons and glial cells in the rat brain, NeuroReport, 1999, Page(s) 1789-1792, Volume 10, Number 8, Publisher: Rapid Communications of Oxford, Oxford, GB, XP009017327	
KC		SUI ET AL., A DNA vector-based RNAi technology to suppress gene expression in mammalian cells, Proceedings of the National Academy of Sciences of USA, 2002, Page(s) 5515-5520, Volume 99, Number 8, Publisher: National Academy of Science, Washington, US, XP002964701	
KC		TUSCHL ET AL., Targeted mRNA degradation by double-stranded RNA in vitro, Genes and Development, 1999, Page(s) 3191-3197, Volume 13, Number 24, Publisher: Cold Spring Harbor Laboratory Press, New York, US, XP002183118	
KC		UEDA, RNAi: A new technology in the post-genomic sequencing era, Journal of Neurogenetics, 2001, Page(s) 193-204, Volume 15, Number 3/4, Publisher: Elsevier, Amsterdam, NL, XP001147227	
KC		WILSON ET AL., Clusterin is a secreted mammalian chaperone, Trends in Biochemical Sciences, 2000, Page(s) 95-98, Volume 25, No. 3, Publisher: Elsevier Publication, Cambridge, EN, XP004202536	
KC		WONG ET AL., Molecular characterization of human TRPM-2/clusterin, a gene associated with sperm maturation, apoptosis and neurodegeneration, European Journal of Biochemistry, 1994, Page(s) 917-925, Volume 227, Number 3, XP 001146404	

Examiner Signature	<i>Kerby Chong</i>	Date Considered	7.12.05
--------------------	--------------------	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Application Number	10/646,436
		Filing Date	8/21/2003
		First Named Inventor	Gleave et al.
		Art Unit	1645
		Examiner Name	
Sheet 4 of 4	Attorney Docket Number	UBC.P-030	

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
EW		ZELLWEGER ET AL., Antitumor Activity of Antisense Clusterin Oligonucleotides is Improved in Vitro and in Vivo by Incorporation of 2'-O-(2-Methoxy)Ethyl Chemistry, Journal of Pharmacology and Experimental Therapeutics, 2001, Page(s) 934-940, Volume 298, Number 3, XP002262318	

Examiner Signature	Kuberly Chong	Date Considered	7/11/05
--------------------	---------------	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



ATTORNEY DOCKET NO. UBC.P-030

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE STATEMENT
BY APPLICANT

Application No: 10/646,436
Filing Date: August 21, 2003
First Named Inventor: Gleave, et al.
Confirmation No.: 9171
Group Art Unit: 1645
Examiner Name:
Attorney Docket No.: UBC.P-030

FOREIGN PATENT DOCUMENTS

Examiner's Initials	Office	Number	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document
KC	WO	00/69454	Chakrabarty, et al.	November 23, 2000

Examiner's Initials	OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS
KC	Chacko, et al.: "Double-Stranded Ribonucleic Acid Decreases C6 Rat Glioma Cell Numbers: Effects on Insulin-Like Growth Factor I Gene Expression and Action"; Endocrinology, Vol. 141, No. 10: 3546-3555; October 2000.
KC	Miyake, et al.: "Castration-Induced Up-Regulation of Insulin-Like Growth Factor Binding Protein-5 Potentiates Insulin-Like Growth Factor-I Activity and Accelerates Progression to Androgen Independence in Prostate Cancer Models"; Cancer Research Vol. 60, No. 11: 3058-3064, June 1, 2000.
KC	Pavelić, et al.: "Insulin-Like Growth Factor Family and Combined Antisense Approach in Therapy of Lung Carcinoma"; Molecular Medicine Vol. 8, No. 3: 149-157, March 2002.

This Information Disclosure Citation List is being submitted as a substitute for Form PTO-1449. The Examiner is requested to place his or her initials on the lines adjacent to the citations to indicate that the reference has been considered. The Examiner is further requested to fill in his or her name and the date the information was considered in blocks at the bottom of this substitute for Form PTO-1449.

Examiner:

Kimberly Chang

Date Considered:

7-11-05